This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.
Newly diagnosed, histologically confirmed non-keratinizing carcinoma (WHO classification).
Stage I-III disease (AJCC 9th edition).
Tumor extends to nasal cavity (including nasal septum).
No distant metastasis (M0).
Keratinizing squamous cell carcinoma (WHO Type I) or basaloid squamous cell carcinoma.
Age <18 or >70 years.
Recurrent disease or distant metastasis.
No tumor extension into the nasal cavity (including the nasal septum).
Hai-Qiang Mai,MD,PhD
Lead sponsor
Sun Yat-sen University
Sponsor institution
First People's Hospital of Foshan
Collaborator
Affiliated Hospital of Guangdong Medical University
Collaborator
The Wuzhou Red Cross Hospital
Collaborator
The Fourth Affiliated Hospital of Guangxi Medical University
Collaborator
Zhongshan City People 's Hospital
Collaborator